Based on the observation that childhood asthma usually occurs after a viral respiratory tract infection, the central hypothesis of the project is that repeated, acute infection-mediated events may reprogram the immune system to predispose towards a chronic inflammation pattern.
The PreDicta consortium integrates 14 partners from 9 European countries that will work together during five years under the coordination of Prof Nikos Papadopoulos from the National and Kapodistrian University of Athens. Leading core units of the consortium have substantially contributed to our current understanding of the role of respiratory infections in asthma, the immuno-inflammatory processes involved and the development of diagnostic and therapeutic approaches for this disease. This academic effort employing the latest technologies of molecular biology, virology and cytology is complemented by the participation of BIOMAY, an Austrian company fully dedicated to the development of novel diagnostic and immunotherapeutic approaches for allergic diseases and asthma.
The final objective of PreDicta is, by the end of the programme, to be able to predict more accurately the predisposing risk factors for the development of respiratory allergies and to interfere more effectively with the disease process by targeting causative agents rather than symptoms.
Predicta FP7 contract no: 260895
Predicta’s presentation video:
PreDicta Update, December 2014
Towards serological tests for the identification of RV strains causing asthma exacerbationsWork from PreDicta provides for the first time evidence that increases of antibodies against a portion of the rhinovirus coat protein VP1 might be strain-specific surrogate markers for the severity of rhinovirus-induced respiratory symptoms. Read more here.
Last updated 02 December 2014